Background: Attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (C1-INH-HAE) usually begin during childhood or adolescence. However, limited data are available regarding indications and modalities of treatment of children. This study evaluated recombinant human C1-INH (rhC1-INH) for HAE attacks in children. Methods: This open-label, phase 2 study included children aged 2-13 years with C1-INH-HAE. Eligible HAE attacks were treated intravenously with rhC1-INH 50 IU/kg body weight (maximum, 4200 IU). The primary end-point was time to beginning of symptom relief (TOSR; ≥20 mm decrease from baseline in visual analog scale [VAS]
| INTRODUC TI ON
Hereditary angioedema (HAE) due to C1 esterase inhibitor (C1-INH) deficiency (C1-INH-HAE) is a rare disorder caused by mutations in the SERPING1 gene. 1 Functional deficiency of the C1-INH protein leads to disinhibition of the complement 2 and contact 3 enzyme cascades, causing overproduction of bradykinin and resulting in increased vascular permeability and fluid leakage to surrounding tissues. 4, 5 HAE is characterized by unpredictable, acute, recurring episodes of angioedema in subcutaneous and/or submucosal tissues. Angioedema episodes can occur in various locations, including the abdomen, periphery, oro-facial/pharyngeal/laryngeal region, or urogenital region. 1, 6 HAE attacks may be painful and disfiguring, and, in the case of upper airway attacks, potentially life-threatening. 6, 7 Furthermore, HAE negatively affects patient quality of life and mood (eg, anxiety, depression), both during and between HAE attacks. 8, 9 Onset of HAE attacks typically occurs during childhood or adolescence. 10 Studies have found mean age of symptom onset to be 4-14 years, [10] [11] [12] [13] [14] [15] with onset by age 10 in approximately 50% of patients. 11, 16, 17 Early symptom onset is often associated with a more severe disease course. 11, 13, 16 This is particularly troubling because diagnosis of HAE has been reported to be a median of 8.5 years from time of symptom onset. 18 International consensus recommendations delineate acute treatment of HAE attacks in a pediatric population. 10, 19 In principle, shorter time to treatment of attacks has been shown to improve clinical outcomes. 19, 20 Despite progress made during the last decade with introduction of novel treatments for HAE, there is a paucity of evidence-based treatment options for children. 10 Recombinant human C1 esterase inhibitor (rhC1-INH) is among the options for adults and adolescents. It is purified from the milk of rabbits 5 and approved in multiple countries for treatment of HAE attacks. The efficacy and safety of rhC1-INH for management of HAE attacks have been demonstrated in adolescents and adults in randomized, placebo-controlled trials, 21, 22 open-label extension studies, [23] [24] [25] and pooled analyses. 26 In addition, data published in 2017 showed rhC1-INH to be efficacious and well tolerated as prophylactic therapy in individuals aged 13 years or older with C1-INH-HAE. 27 The objective of the current study was to evaluate the efficacy and safety of rhC1-INH for acute treatment of HAE attacks in children.
| ME THODS

| Study design
This open-label, phase 2, multicenter, multinational clinical study was conducted from January 2012 to July 2017 at 18 centers in 10 countries (ClinicalTrials.gov identifier: NCT01359969). This study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the ethical principles of the Declaration of Helsinki, and applicable local regulatory requirements. Study protocols were approved by an institutional review board or independent ethics committee at each site. All patients provided assent to study participation, and a parent/legal guardian provided written informed consent before study procedures were initiated.
| Study participants
Children aged 2-13 years with a clinical and confirmed laboratory diagnosis (C1-INH activity <50% of normal) of C1-INH-HAE were eligible for the study. Key exclusion criteria included a diagnosis of acquired C1-INH deficiency, allergy to rabbits, and medical history of 10 HAE attacks previously treated with study medication. An attack was eligible for treatment if the patient presented to the site with an onset of attack symptoms within 5 hours of evaluation, had at least one anatomic location involved, and had an investigator rating of at least moderate intensity (≥3; range, 0-5) at presentation, with no indication of spontaneous regression.
| Intervention
Eligible patients received within 5 minutes an intravenous injection of rhC1-INH (Ruconest ® ; Pharming Technologies B.V.) 50 IU/kg of body weight (maximum dose, 4200 IU). One additional dose could be administered at the investigator's discretion, based on clinical response. No more than two doses were to be administered within 24 hours. Additional 
| Assessments
| Statistics
No formal sample size was calculated a priori, and study enrollment continued until at least 20 patients were treated for at least one 
| RE SULTS
| Patient population
Of 57 children screened and considered eligible for treatment, 20 received rhC1-INH for at least one HAE attack and were included in the ITT and efficacy populations ( Table 1) Fifteen children (75.0%) completed the study. Five children discontinued study participation due to consent withdrawal: one patient left the country, one patient was no longer interested in continuing, one patient's mother decided not to attend additional study visits for personal reasons, one patient preferred to treat HAE attacks at home with a different medication, and one patient was no longer considered a child based on age and weight (ie, obese). 
| Efficacy
Seventy (95.9%) of 73 HAE attacks were treated with a single dose.
One child received a second dose for HAE attacks 3 and 8, and one child received a second dose for attack 3. Median TOSR based on VAS score (primary end-point) for the 73 HAE attacks was 60.0 minutes (95% confidence interval [CI], 60.0-65.0 minutes). For the first HAE attack, the median TOSR was 60.0 minutes, and most children had TOSR within 4 hours (240 minutes; Figure 1A ). Data were consistent across individual HAE attacks, with a median TOSR of approximately 60.0 minutes post-treatment and overlapping 95% CIs ( Figure 1B ). Across individual HAE attacks, median TTMS was consistent, at approximately 120 minutes post-treatment with overlapping 95% CIs ( being self-limited, resolving spontaneously, and not recurring upon re-treatment, the authors speculate that these events were probably related to a viral infection.
| Functional C1-INH concentrations
| Safety
There was no evidence of an increase in incidence of AEs in children treated for more than one HAE attack. In addition, most AEs were mild in intensity, with no evidence of a relationship between HAE attack number and AE intensity ( Table 3) demonstrated the efficacy and safety of rhC1-INH in patients aged 12 years and older, 21, 22 and the current study showed that rhC1- 
| D ISCUSS I ON
CO N FLI C T O F I NTE R E S T S
AUTH O R CO NTR I B UTI O N S
A Reshef, VG-P, A Relan, and BG were involved in the conception and design of the study. A Reshef, VG-P, AK, SK, MK-R, DM, HF, VG, SF, and MM were investigators in the study and involved in data acquisition and interpretation. All authors critically reviewed, revised, and approved the manuscript for publication and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
O RCI D
Avner Reshef https://orcid.org/0000-0002-3324-7072 Aharon Kessel https://orcid.org/0000-0003-4141-2100
